Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade

被引:11
|
作者
Trescher, Karola [1 ]
Bauer, Michael [1 ]
Dietl, Wolfgang [1 ]
Hallstroem, Seth [2 ]
Wick, Nikolaus [3 ]
Wolfsberger, Margarita [4 ]
Ullrich, Robert [3 ]
Juergens, Guenther [2 ]
Wolner, Ernst [1 ]
Podesser, Bruno K. [1 ]
机构
[1] Med Univ Graz, Ludwig Boltzmann Cluster Cardiovasc Res, Graz, Austria
[2] Med Univ Graz, Inst Physiol Chem, Ctr Physiol Med, Graz, Austria
[3] Vienna Med Univ, Dept Pathol, Vienna, Austria
[4] Vienna Med Univ, Dept Pediat, Vienna, Austria
来源
关键词
ANGIOTENSIN-CONVERTING ENZYME; NITRIC-OXIDE; ISCHEMIA-REPERFUSION; ANTAGONIST BOSENTAN; INJURY; INHIBITION; OVEREXPRESSION; RECOVERY;
D O I
10.1016/j.jtcvs.2008.10.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Ischemia/reperfusion injury caused by cardioplegic arrest is still a major challenge in patients with reduced left ventricular function. We investigated the effect of chronic versus acute administration of the selective endothelin-A receptor antagonist (ERA) TBC-3214Na during ischemia/reperfusion in failing hearts. Methods: Male Sprague-Dawley rats underwent coronary ligation. Three days after myocardial infarction (MI), 19 randomly assigned animals (ERA chronic) were administered TBC-3214Na continuously with their drinking water, 29 MI rats received placebo, and 3 rats died during the observation period. Six weeks after infarction, hearts were evaluated in a blood-perfused working heart model during 60 minutes of ischemia and 30 minutes of reperfusion. In 14 MI rats, TBC-3214Na ( ERA acute) was added to the cardioplegic solution during ischemia. Thirteen MI rats served as control. Results: At a similar infarct size, postischemic recovery of cardiac output (ERA chronic: 91% +/- 10%, ERA acute: 86% +/- 11% vs control: 52% +/- 15%; P < .05) and external heart work (ERA chronic: 90% +/- 10%, ERA acute: 85% +/- 13% vs control: 51% +/- 17%; P < .05) was significantly enhanced in both TBC3214Na- treated groups whereas recovery of coronary flow was only improved in ERA acute rats (ERA acute: 121% +/- 23% vs ERA chronic: 75% +/- 13%; control: 64% +/- 15%; P < .05). Blood gas measurements showed enhanced myocardial oxygen delivery and consumption with acute TBC-3214Na therapy. Additionally, high-energy phosphates (phosphocreatine) were significantly higher and transmission electron microscopy revealed less ultrastructural damage under acute TBC-3214Na administration. Conclusion: Acute endothelin-A receptor blockade is superior to chronic blockade in attenuating ischemia/reperfusion injury in failing hearts. Therefore, acute endothelin-A receptor blockade might be an interesting option for patients with heart failure undergoing cardiac surgery.
引用
收藏
页码:1005 / U243
页数:8
相关论文
共 50 条
  • [41] Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist
    Sudoh, K
    Yuyama, H
    Noguchi, Y
    Fujimori, A
    Ukai, H
    Ohtake, A
    Sato, S
    Sasamata, M
    Miyata, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 : S390 - S393
  • [42] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [43] Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure -: The heart failure ETA receptor blockade trial (HEAT)
    Lüscher, TF
    Enseleit, F
    Pacher, R
    Mitrovic, V
    Schulze, MR
    Willenbrock, R
    Dietz, R
    Rousson, V
    Hürlimann, D
    Philipp, S
    Notter, T
    Noll, G
    Ruschitzka, F
    CIRCULATION, 2002, 106 (21) : 2666 - 2672
  • [44] Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - A comparison of selective and combined endothelin receptor blockade
    Goddard, J
    Johnston, NR
    Hand, MF
    Cumming, AD
    Rabelink, TJ
    Rankin, AJ
    Webb, DJ
    CIRCULATION, 2004, 109 (09) : 1186 - 1193
  • [45] Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists
    Tasker, AS
    Sorensen, BK
    Jae, HS
    Winn, M
    vonGeldern, TW
    Dixon, DB
    Chiou, WJ
    Dayton, BD
    Calzadila, S
    Hernandez, L
    Marsh, KC
    WuWong, JR
    Opgenorth, TJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (03) : 322 - 330
  • [46] Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, bosentan, in experimental renal ischemia reperfusion injury
    Kazimoglu, H.
    Uysal, E.
    Dokur, M.
    Gurer, A. O.
    Batcioglu, K.
    Uyumlu, B. A.
    Petekkaya, E.
    Karadag, M.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2020, 121 (08): : 547 - 553
  • [47] Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling
    Ambalavanan, N
    Bulger, A
    Murphy-Ullrich, J
    Oparil, S
    Chen, YF
    PEDIATRIC RESEARCH, 2005, 57 (05) : 631 - 636
  • [48] Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
    Verhaar, MC
    Strachan, FE
    Newby, DE
    Cruden, NL
    Koomans, HA
    Rabelink, TJ
    Webb, DJ
    CIRCULATION, 1998, 97 (08) : 752 - 756
  • [49] Endothelin-A Receptor Blockade and Inhaled Nitric Oxide in a Porcine Model of Meconium Aspiration Syndrome
    Lara S Shekerdemian
    Daniel J Penny
    Pia K Ryhammer
    Jayne A Reader
    Hanne B Ravn
    Pediatric Research, 2004, 56 : 353 - 358
  • [50] Endothelin-A receptor blockade and inhaled nitric oxide in a porcine model of meconium aspiration syndrome
    Shekerdemian, LS
    Penny, DJ
    Ryhammer, PK
    Reader, JA
    Ravn, HB
    PEDIATRIC RESEARCH, 2004, 56 (03) : 353 - 358